Varicella Pneumonia Requires IV Acyclovir

• by Andrea Surnit

• April 24, 2026

4CMenB tied to modest gonorrhea protection in real-world study

The 38.4% reduction in gonorrhea risk “could translate into preventing a substantial number of infections and complications.”

• by Julia Cipriano, MS, CMPP

• September 9, 2026

• 4 min

FDA approves pritelivir for refractory HSV lesions

In a phase 3 trial, complete lesion healing occurred in 63% of patients receiving pritelivir vs. 34% receiving comparator treatments.

• by Teraya Smith

• October 9, 2026

• 2 min

Heterogeneous reduction in pediatrics RSV hospitalizations following regional nirsevimab immunization strategies: a multicenter study

• by Federica Attaianese, Sandra Trapani, Ilaria Alberti, Maurizio Aricò, Marina Attanasi, Giulia Bertolucci, Silvia Bressan, Désirée Caselli, Veronica Casotto, Salvatore Cazzato, Francesco Chiarelli, Enrico Felici, Anna Frusciante, Maria Antonia Galeone, Silvia Garazzino, Antonietta Giannattasio, Eloisa Gitto, Antonio Guerriero, Fiorentina Guida, Giovanna Iudica

• September 14, 2026